Misplaced Pages

Matthew Hebden Porteus is Sutardja Chuk Professor of Definitive and Curative Medicine at Stanford University. In 2003, as a postdoctoral fellow in David Baltimore's lab at the California Institute of Technology, Porteus was the first to demonstrate precise gene editing in human cells using chimeric nucleases.

He graduated magna cum laude from Harvard University and completed his MD and PhD at Stanford University. For his post-doctoral work he trained with David Baltimore at MIT and Caltech. He is a scientific founder of CRISPR Therapeutics and an academic founder of Graphite Bio.

He has an h-index of 69 according to Google Scholar.

References

1. "Matthew Porteus". Stanford University School of Medicine. Retrieved 23 June 2021.
2. Porteus MH, Baltimore D (May 2003). "Chimeric nucleases stimulate gene targeting in human cells". Science. 300 (5620): 763. doi:10.1126/science.1078395. PMID 12730593. S2CID 34460337.
3. ^ "Dr. Matthew Porteus". CRISPR Therapeutics. Retrieved 23 June 2021.
4. "There Are Now Two Pushes to Treat Sickle Cell Disease With CRISPR". CRISPR Medicine News. Retrieved 26 June 2021.
5. "About Us: Academic Founders". Graphite Bio. Retrieved 26 June 2021.
6. "Matthew Porteus". Google Scholar. Retrieved 28 October 2023.

External links

• Matthew Porteus publications indexed by Google Scholar

This biographical article about a scientist is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Living people
• Harvard University alumni
• Stanford University alumni
• University of Texas Southwestern Medical Center faculty
• Stanford University faculty
• Scientist stubs